[Federal Register Volume 78, Number 12 (Thursday, January 17, 2013)]
[Notices]
[Page 3906]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-00878]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of a Co-Exclusive License: Adenovirus-Based 
Controls and Calibrators for Molecular Diagnostics of Infectious 
Disease Agents

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services (HHS), is contemplating the 
grant of a worldwide co-exclusive license, to practice the inventions 
embodied in US patent 6,013,638 (HHS Reference E-129-1991/0-
US-03), issued January 11, 2000 and entitled ``Adenovirus Comprising 
Deletions on the E1A, E1B And E3 Regions for Transfer of Genes to the 
Lung'', and US patent 6,136,594 (HHS Reference E-129-1991/1-
US-03), issued October 24, 2000, and entitled ``Replication Deficient 
Recombinant Adenovirus Vector'' to Life Technologies Corporation (LTC) 
of Carlsbad, California. The United States of America is an assignee of 
the rights of the above inventions.
    The field of use may be limited to the ``use of adenovirus-based 
recombinant constructs as controls and calibrators for molecular 
diagnostics for infectious disease agents.''

DATES: Only written comments and/or applications for a license received 
by the NIH Office of Technology Transfer on or before February 19, 2013 
will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Uri Reichman, Ph.D., M.B.A, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4616; 
Facsimile: (301) 402-0220; Email: [email protected].

SUPPLEMENTARY INFORMATION: The invention relates to recombinant 
adenovirus vectors containing foreign DNA. Such vectors can be used for 
gene transfer, therapeutics, and protein expression. The technology can 
also be utilized to make calibrators and controls for molecular 
diagnostics (e.g. real time PCR tests).
    The prospective co-exclusive license will comply with the terms and 
conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-
exclusive license may be granted unless, within thirty (30) days from 
the date of this published notice, NIH receives written evidence and 
argument that establishes that the grant of the license would not be 
consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

    Dated: January 11, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-00878 Filed 1-16-13; 8:45 am]
BILLING CODE 4140-01-P